KYMERA THERAPEUTICS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $1.47M, a 32.37% increase year-over-year.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $573.00K, a 35.18% decline year-over-year.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $1.11M, a 1.94% decline year-over-year.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.69M, a 16.50% decline from fiscal 2024.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $2.02M, a 43.43% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $1.41M, a 22.35% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $1.15M, a 45.94% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $1.47M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $573.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.69M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $1.11M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $884.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.02M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | |
| 2024-06-30 | $1.13M 10-Q · filed 2025-08-11 | |
| 2023-12-31 | $445.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.41M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | |
| 2023-06-30 | $962.00K 10-Q · filed 2024-08-07 | |
| 2022-12-31 | $894.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.15M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | |
| 2022-06-30 | $256.00K 10-Q · filed 2023-08-03 | |
| 2021-12-31 | $481.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $788.00K 10-K · filed 2024-02-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | |
| 2021-06-30 | $307.00K 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |